EUVIMEDEUVIMED entdecken
Fallbericht

Epilepsy with eyelid myoclonia in the setting of de novo pathogenic variant in ATP1A3

Maksim Parfyonov iD, Alina Ivaniuk, Sumit Parikh, Elia Pestana-Knight

Epileptic Disorders · 2023

DOI: 10.1002/epd2.20086 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Epileptic Disorders, 2023. Verfasst von Maksim Parfyonov und 3 weiteren Autor:innen. Beteiligte Einrichtung: Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Epilepsy, Dystonic Disorders. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 9 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mutations in the ATP1A3 gene have been associated with several syndromes, including rapid‐onset dystonia‐parkinsonism, alternating hemiplegia of childhood, and cerebellar ataxia, areflexia, pes cavus, optic atrophy, and sensorineural hearing loss. In this clinical commentary, we report a 2‐year‐old female patient with de novo pathogenic variant in the ATP1A3 gene associated with an early‐onset form of epilepsy with eyelid myoclonia. The patient had frequent eyelid myoclonia occurring 20–30 times per day, without loss of awareness or other motor manifestations. EEG showed generalized polyspikes and spike‐and‐wave complexes maximal in the bifrontal regions, with prominent eye closure sensitivity. A sequencing‐based epilepsy gene panel revealed a de novo pathogenic heterozygous variant in ATP1A3 . The patient showed some response to flunarizine and clonazepam. This case highlights the importance of considering ATP1A3 mutations in the differential diagnosis of early‐onset epilepsy with eyelid myoclonia and the potential benefit of flunarizine in improving language and coordination development in patients with ATP1A3 ‐related disorders.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EpilepsyDystonic DisordersFemaleHumansChild, PreschoolFlunarizineHemiplegiaMutationEyelidsSodium-Potassium-Exchanging ATPase

Stichwörter der Autor:innen

ATP1A3Jeavons syndromeepilepsy with eyelid myoclonia

Substanzen

FlunarizineATP1A3 protein, humanSodium-Potassium-Exchanging ATPase

Autor:innen und Institutionen

  • Epilepsy Center, Neurological Institute, Cleveland Clinic, Cleveland, Ohio, USA.
  • Neurometabolism & Neurogenetics, Cleveland Clinic, Cleveland, Ohio, USA.

ORCID-Profile: Maksim Parfyonov

Zitieren

APA

Parfyonov, M., Ivaniuk, A., Parikh, S., & Pestana-Knight, E. (2023). Epilepsy with eyelid myoclonia in the setting of de novo pathogenic variant in ATP1A3. Epileptic Disorders. https://doi.org/10.1002/epd2.20086

Vancouver

Parfyonov M, Ivaniuk A, Parikh S, Pestana-Knight E. Epilepsy with eyelid myoclonia in the setting of de novo pathogenic variant in ATP1A3. Epileptic Disorders. 2023. doi:10.1002/epd2.20086

BibTeX
@article{Parfyonov2023,
  author = {Parfyonov, Maksim and Ivaniuk, Alina and Parikh, Sumit and Pestana-Knight, Elia},
  title = {Epilepsy with eyelid myoclonia in the setting of de novo pathogenic variant in ATP1A3},
  journal = {Epileptic Disorders},
  year = {2023},
  doi = {10.1002/epd2.20086}
}
Kostenlos starten →